Please login to the form below

Not currently logged in
Email:
Password:

MyoKardia appoints COO and medical affairs VP

Dr June Lee and Dr Radhika Tripuraneni join the precision medicines specialist

MyoKardia June LeeCalifornia, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice president of medical affairs.

Dr Lee (pictured right) joins the cardiology specialist from the University of California, San Francisco (UCSF), where she was director of the therapeutics and digital health technologies accelerator programme, Catalyst, at the Clinical and Translational Science Institute and a professor at the UCSF School of Medicine.

Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech.

MyoKardia Dr Radhika TripuraneniMeanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of therapeutic areas - including rare and cardiovascular diseases - to MyoKardia.

Most recently, she served as vice president for medical affairs at Alexion Pharmaceuticals, and was cardiovascular medical director at Gilead Sciences before this. She also brings experience as global medical director and global medical affairs lead for two therapeutic areas at Genzyme.

Tassos Gianakakos, MyoKardia's chief executive officer, said: “I am thrilled to welcome these two exceptional life sciences leaders to the MyoKardia team at this pivotal time as we expand our pipeline and advance new clinical candidates.

“Their expertise and counsel will broaden our base of leadership and support our mission to change the world for patients with serious cardiovascular disease.”

6th February 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...